Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AAME vs MURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AAME Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–3 Matrix Metrics)

AAME Overall Winner 6-Pillar Tally: AAME 5 – 0 MURA (1 Tie) Matrix Metrics: AAME 6 – 3 MURA

As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Mural Oncology plc (MURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas MURA carries 44.8/100 (HOLD) at $2.03 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MURA currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AAME 42.1/100 HOLD), AAME captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 0.0% operating margin) and revenue trajectory (+4.8% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: AAME trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile MURA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAME vs MURA
AAME NASDAQ Head-to-Head Winner
Atlantic American Corp
Life Insurance
$1.18
-6.35% 1D
Market Cap $25.7M
TTM Revenue $210M
Forward P/E 7.4x
Beta / 30D Vol 0.92β · 116% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 45.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.9 · SMA20: $1.23 · SMA50: $1.26
MURA NASDAQ
Mural Oncology plc Ordinary Shares
Pharmaceutical Preparations
$2.03
+0.0% 1D
Market Cap $35.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.39β · 16% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 25.0 Fund 36.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.0%) with fading momentum, RSI 37
RSI-14: 36.7 · SMA20: $2.07 · SMA50: $2.08

6-Pillar Scorecard Institutional Category Breakdown (AAME 5 – 0 MURA)

Columns: Metric · AAME · MURA
1. Valuation Multiples AAME
Forward P/E 7.4x N/M
Trailing P/E 4.5x N/M
PEG Ratio 2.43x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale AAME
Revenue Growth (YoY) +4.8% +0.0%
Earnings Growth (YoY) -59.7% +0.0%
TTM Revenue (USD) $210M N/A
Market Cap $25.7M $35.0M
3. Profitability & Quality AAME
Gross Margin 13.0% N/A
Operating Margin 5.1% 0.0%
Net Profit Margin 2.9% 0.0%
Return on Equity (ROE) 5.2% -103.9%
4. Balance Sheet & Cash Flow AAME
Cash Generation (TTM) $24M N/A
Cash Flow Margin 11.5% N/A
Net Cash / Leverage $3.3M Net Debt (0.34x D/E) $3.19 Book/Sh · -103.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat AAME
OpEx & R&D Intensity 7.9% of Rev ($17M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance - Life Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAME (6) vs MURA (3)
Institutional Metric AAME MURA Criterion Row Edge
Market Capitalization
Scale
$25.7M $35.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
4.5x N/M Lower Multiple AAME
Forward P/E Ratio
Valuation
7.4x N/M Lower Multiple AAME
Revenue Growth (YoY)
Growth
+4.8% +0.0% Higher Growth AAME
Operating Margin (TTM)
Profitability
5.1% 0.0% Higher Margin AAME
Net Profit Margin
Profitability
2.9% 0.0% Higher Margin AAME
Return on Equity (ROE)
Capital Efficiency
5.2% -103.9% Higher ROE AAME
52-Week Range Position
Momentum
8% ($1–$3) 28% ($1–$5) Stronger Trend MURA
Beta / 30D Volatility
Risk Regime
0.92β · 116% Vol 0.39β · 16% Vol Lower Realized Risk MURA
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite MURA
Trailing 12M Revenue (USD)
Operating Scale
$210M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.43x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$24M ($3.3M Net Debt (0.34x D/E)) N/A ($3.19 Book/Sh · -103.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MURA +15.34 pp
AAME: -18.21% · MURA: -2.87%
3M Horizon MURA +15.34 pp
AAME: -18.21% · MURA: -2.87%
6M Horizon MURA +15.34 pp
AAME: -18.21% · MURA: -2.87%
1Y Horizon MURA +15.34 pp
AAME: -18.21% · MURA: -2.87%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAME vs MURA. Trailing 12-month operating profitability (AAME 5.1% vs MURA 0.0%) and valuation multiples (AAME 7.4x vs MURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AAME ADR TTM Benchmark FX-Normalized USD
TTM Revenue$210M
Gross Margin13.0%
Op. Margin5.1%
ROE / Fwd P/E5.2% · 7.4x
MURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-103.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAME UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MURA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAME Moat Profile Cyclical / Execution-Driven Positioning
Insurance - Life Operator
Competes within the Insurance - Life value chain with $25.7M market capitalization and 5.1% operating margin.
OpEx & R&D Reinvestment 7.9% of Rev ($17M)
90D Engineering Disclosures 0 Published
MURA Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $35.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AAME vs MURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Mural Oncology plc (MURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas MURA carries 44.8/100 (HOLD) at $2.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MURA currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AAME 42.1/100 HOLD), AAME captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 0.0% operating margin) and revenue trajectory (+4.8% vs. +0.0% YoY). Technical & Structure Timing Caution: AAME trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile MURA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAME leads the Growth & Scale pillar: AAME posts +4.8% YoY revenue growth and -59.7% YoY earnings growth on $210M TTM revenue (13.0% gross margin, 5.1% operating margin), compared with MURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AAME generates $210M in USD-normalized revenue versus N/A for MURA. In operating R&D and SG&A reinvestment, AAME deploys 7.9% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MURA.

AAME screens cheaper on headline valuation multiples. AAME trades at 7.4x Forward P/E, 4.5x Trailing P/E, 2.43x PEG, and 0.1x EV/Revenue (11.5% FCF margin), whereas MURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAME (5.2% ROE) versus MURA (-103.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AAME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 116% Vol realized risk). By comparison, MURA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 16% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.